
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Management of Irritable Bowel Syndrome (IBS): A Synthesized Guideline</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Management of Irritable Bowel Syndrome (IBS): A Synthesized Guideline</strong></summary>
            <div>
                <ul><li>- This mind map synthesizes and compares recommendations from two major clinical guidelines:</li><li>- <b>BSG (British Society of Gastroenterology)</b>: Vasant DH, et al. Gut 2021;0:1–27.</li><li>- <b>ACG (American College of Gastroenterology)</b>: Lacy BE, et al. Am J Gastroenterol 2021;116:17–44.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the NNT (Number Needed to Treat) with soluble fiber (ispaghula) for IBS symptoms, according to the BSG-cited meta-analysis? <q><b>7</b></q></li><li>- The ACG guideline contraindicates eluxadoline in patients without a gallbladder due to the risk of what specific adverse event? <q><u>Sphincter of Oddi spasm</u></q></li><li>- According to the BSG guideline, what is the maximum recommended daily dose for amitriptyline when used as a gut-brain neuromodulator for IBS? <q><b>30–50 mg</b></q></li><li>- The ACG guideline notes that what percentage of patients with IBS-D may have Bile Acid Malabsorption (BAM) based on SeHCAT testing? <q><u>28.1%</u></q></li><li>- The BSG guideline states that moving from Rome III to Rome IV criteria for IBS diagnosis reduces the worldwide prevalence from approximately 9.2% to what percentage? <q><b>3.8%</b></q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>IBS Definition & Diagnostic Criteria</strong></summary>
            <div>
                <ul><li>- IBS is re-classified as a <b>Disorder of Gut-Brain Interaction</b>, moving away from the term 'functional disorder'.</li><li>- The diagnosis is based on a characteristic pattern of symptoms, primarily abdominal pain associated with changes in bowel habits.</li></ul>
                
        <details>
            <summary><strong>Rome IV Criteria</strong></summary>
            <div>
                <ul><li>- <u>Recurrent abdominal pain</u>, on average, at least <q><b>1 day per week</b></q> in the last 3 months, associated with ≥2 of the following:</li><li>- Related to defecation.</li><li>- Associated with a change in stool frequency.</li><li>- Associated with a change in stool form (appearance).</li><li>- Criteria must be fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis.</li></ul>
                
        <details>
            <summary><strong>IBS Subtypes (based on Bristol Stool Form Scale)</strong></summary>
            <div>
                <ul><li>- <b>IBS-C (Constipation)</b>: >25% of BMs are type 1 or 2, and <25% are type 6 or 7.</li><li>- <b>IBS-D (Diarrhoea)</b>: >25% of BMs are type 6 or 7, and <25% are type 1 or 2.</li><li>- <b>IBS-M (Mixed)</b>: >25% of BMs are type 1 or 2, AND >25% are type 6 or 7.</li><li>- <b>IBS-U (Unclassified)</b>: Patients who meet criteria for IBS but do not fit into the other subgroups.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Clinical Application of Criteria: <u>Consensus & Discrepancy</u></strong></summary>
            <div>
                <ul><li>- Both guidelines agree on using symptom-based criteria for diagnosis.</li><li>- However, they differ on which criteria are most practical in clinical settings.</li></ul>
                
        <details>
            <summary><strong>BSG Guideline View</strong></summary>
            <div>
                <ul><li>- Recommends the <b>NICE guideline definition</b> as more pragmatic for primary care.</li><li>- <u>Definition</u>: Abdominal pain/discomfort associated with altered bowel habit for at least <q>6 months</q>, in the absence of alarm symptoms.</li><li>- Argues that Rome IV criteria may be <u>too restrictive</u> for clinical practice, potentially leaving many symptomatic patients without a clear diagnosis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>ACG Guideline View</strong></summary>
            <div>
                <ul><li>- Endorses the use of <b>Rome IV criteria</b> for diagnosis in both clinical and research settings.</li><li>- Emphasizes that accurate subtyping based on Rome IV is critical for selecting appropriate therapy.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diagnostic Strategy: <u>Strong Consensus</u></strong></summary>
            <div>
                <ul><li>- Both guidelines strongly advocate for a <b>positive diagnostic strategy</b> rather than a diagnosis of exclusion.</li></ul>
                
        <details>
            <summary><strong>Rationale</strong></summary>
            <div>
                <ul><li>- <u>BSG</u>: Make a positive diagnosis based on symptoms, absence of alarm features, and normal simple blood/stool tests.</li><li>- <u>ACG</u>: A positive strategy improves time to initiating therapy and is more cost-effective.</li><li>- An 'exclusion' strategy leads to unnecessary testing, increased costs (ACG notes it consumes <q><u>$400 more per patient</u></q>), and does not improve patient reassurance or outcomes.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Alarm Features (Red Flags)</strong></summary>
            <div>
                <ul><li>- Presence of these features warrants further investigation (e.g., colonoscopy) to rule out organic disease.</li><li>- <u>Key Features</u>: Unexplained weight loss, rectal bleeding, family history of IBD or colorectal cancer, iron deficiency anaemia, onset of symptoms at age >50 years (BSG uses >60 for some criteria), abdominal/rectal mass.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Investigations</strong></summary>
            <div>
                <ul><li>- Both guidelines agree on a limited, targeted approach to investigations in patients with typical IBS symptoms and no alarm features.</li></ul>
                
        <details>
            <summary><strong>Initial Diagnostic Tests: <u>Strong Consensus</u></strong></summary>
            <div>
                <ul><li>- A minimal set of tests is recommended to rule out key organic diseases.</li></ul>
                
        <details>
            <summary><strong>BSG Recommendations (Primary Care)</strong></summary>
            <div>
                <ul><li>- <b>All patients</b>: Full Blood Count (FBC), C-Reactive Protein (CRP) or ESR, and <u>Coeliac serology</u>.</li><li>- <b>Patients <45 years with diarrhoea</b>: Add <u>Faecal Calprotectin</u> to exclude IBD.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>ACG Recommendations</strong></summary>
            <div>
                <ul><li>- <b>Patients with IBS-D</b>: <u>Coeliac serology</u> (Strong recommendation).</li><li>- <b>Patients with IBS-D</b>: <u>Faecal Calprotectin</u> and/or CRP to rule out IBD (Strong recommendation).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Tests NOT Routinely Recommended: <u>Strong Consensus</u></strong></summary>
            <div>
                <ul><li>- Both guidelines advise against broad, untargeted testing.</li></ul>
                
        <details>
            <summary><strong>BSG Guideline</strong></summary>
            <div>
                <ul><li>- <u>No role for</u>:</li><li>- Hydrogen breath testing (for SIBO or carbohydrate intolerance).</li><li>- Testing for exocrine pancreatic insufficiency (unless steatorrhoea is present).</li><li>- Food elimination diets based on <b>IgG antibodies</b>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>ACG Guideline</strong></summary>
            <div>
                <ul><li>- <u>Recommend against</u>:</li><li>- Routine stool testing for enteric pathogens (unless high-risk, e.g., for Giardia).</li><li>- Routine testing for food allergies/sensitivities (unless reproducible symptoms suggest a true allergy).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Role of Colonoscopy: <u>Strong Consensus</u></strong></summary>
            <div>
                <ul><li>- <b>Routine colonoscopy is NOT recommended</b> in younger patients with typical IBS symptoms and no alarm features.</li><li>- <u>ACG specifies age</u>: <q><45 years</q>.</li><li>- <u>BSG notes</u>: The yield is extremely low and it does not provide reassurance.</li></ul>
                
        <details>
            <summary><strong>When to Consider Colonoscopy</strong></summary>
            <div>
                <ul><li>- Presence of alarm features.</li><li>- To screen for colorectal cancer per national guidelines (e.g., age >45/50).</li><li>- <u>BSG specific</u>: In IBS-D patients with risk factors for <b>microscopic colitis</b> (female, age <q>≥50</q>, autoimmune disease, watery diarrhoea, use of NSAIDs/PPIs).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Further Specialised Investigations</strong></summary>
            <div>
                <ul><li>- Considered in secondary care for refractory symptoms or diagnostic uncertainty.</li></ul>
                
        <details>
            <summary><strong>Bile Acid Diarrhoea (BAD)</strong></summary>
            <div>
                <ul><li>- <u>BSG</u>: Consider <b>SeHCAT scan</b> or serum 7α-hydroxy-4-cholesten-3-one in IBS-D with atypical features (e.g., nocturnal diarrhoea) or prior cholecystectomy.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Anorectal Physiology</strong></summary>
            <div>
                <ul><li>- <u>Consensus</u>: Consider anorectal manometry (ARM) and balloon expulsion test (BET) in patients with refractory constipation or symptoms of a pelvic floor disorder (e.g., straining, sensation of incomplete evacuation).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>General Management & First-Line Therapies</strong></summary>
            <div>
                <ul><li>- Management should be holistic, starting with lifestyle, diet, and simple pharmacological agents.</li></ul>
                
        <details>
            <summary><strong>Lifestyle</strong></summary>
            <div>
                <ul><li>- <b>Doctor-Patient Relationship</b>: Both guidelines strongly emphasize establishing an effective, empathic relationship as key to successful management.</li><li>- <b>Exercise</b>: BSG strongly recommends regular exercise for all patients with IBS.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Dietary Therapies</strong></summary>
            <div>
                
                
        <details>
            <summary><strong>Fibre: <u>Strong Consensus</u></strong></summary>
            <div>
                <ul><li>- <b>Soluble fibre</b> (e.g., ispaghula/psyllium) is effective for global symptoms.</li><li>- <b>Insoluble fibre</b> (e.g., wheat bran) should be <u>avoided</u> as it can worsen symptoms.</li><li>- <u>BSG</u>: Start at a low dose (<q>3–4 g/day</q>) and titrate up gradually to avoid bloating.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Low FODMAP Diet: <u>Strong Consensus</u></strong></summary>
            <div>
                <ul><li>- Both recommend a trial of a low FODMAP diet for global symptoms.</li><li>- Positioned as a <b>second-line dietary therapy</b> (BSG) or a 'limited trial' (ACG).</li><li>- <u>Crucial point</u>: Must be supervised by a trained dietitian to ensure nutritional adequacy and proper reintroduction of foods.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Diets</strong></summary>
            <div>
                <ul><li>- <b>Gluten-Free Diet</b>: BSG weakly recommends against it due to insufficient evidence.</li><li>- <b>IgG-based Elimination Diets</b>: Both strongly recommend against this approach.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Probiotics</strong></summary>
            <div>
                <ul><li>- <u>Nuanced Discrepancy</u>: Both guidelines are cautious due to heterogeneity of evidence.</li></ul>
                
        <details>
            <summary><strong>BSG Guideline</strong></summary>
            <div>
                <ul><li>- <b>Weak recommendation FOR</b> trying probiotics.</li><li>- States they 'may be an effective treatment' but it's not possible to recommend a specific species or strain.</li><li>- Suggests a trial for up to <q>12 weeks</q> and stopping if no benefit.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>ACG Guideline</strong></summary>
            <div>
                <ul><li>- <b>Conditional recommendation AGAINST</b> probiotics for global symptoms.</li><li>- Cites inconsistent benefits, small study sizes, and lack of rigorous endpoints in trials.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>First-Line Pharmacotherapies</strong></summary>
            <div>
                
                
        <details>
            <summary><strong>Antispasmodics & Peppermint Oil: <u>Key Discrepancy</u></strong></summary>
            <div>
                <ul><li>- The guidelines differ significantly on the role of antispasmodics, largely due to the availability of agents and quality of evidence.</li></ul>
                
        <details>
            <summary><strong>BSG Guideline</strong></summary>
            <div>
                <ul><li>- <b>Weak recommendation FOR</b> certain antispasmodics (e.g., hyoscine butylbromide) and peppermint oil for global symptoms and pain.</li><li>- Notes that alverine and mebeverine did not show benefit over placebo in their meta-analysis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>ACG Guideline</strong></summary>
            <div>
                <ul><li>- <b>Conditional recommendation AGAINST</b> antispasmodics available in the US (dicyclomine, hyoscyamine) due to poor quality, decades-old data.</li><li>- <b>Conditional recommendation FOR</b> peppermint oil to provide relief of global symptoms.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Loperamide (for IBS-D)</strong></summary>
            <div>
                <ul><li>- <u>Consensus on use for diarrhoea</u>, but not for global symptoms.</li><li>- <u>BSG</u>: Strong recommendation, but notes common side effects (pain, bloating, constipation) may limit tolerability.</li><li>- <u>ACG</u>: Notes it improves diarrhoea but not global IBS symptoms, so not recommended as a primary therapy for IBS-D.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Polyethylene Glycol (PEG) (for IBS-C)</strong></summary>
            <div>
                <ul><li>- <u>Discrepancy in Recommendation</u>: Both agree it does not treat pain, but frame their recommendation differently.</li></ul>
                
        <details>
            <summary><strong>BSG Guideline</strong></summary>
            <div>
                <ul><li>- <b>Weak recommendation FOR</b> PEG as an effective treatment for constipation in IBS.</li><li>- Acknowledges abdominal pain is a common side effect.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>ACG Guideline</strong></summary>
            <div>
                <ul><li>- <b>Conditional recommendation AGAINST</b> PEG for relieving <u>global IBS symptoms</u>.</li><li>- Rationale: While it improves bowel movements, RCTs failed to show it improves abdominal pain, a core component of IBS.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Second-Line Therapies</strong></summary>
            <div>
                <ul><li>- For patients whose symptoms are refractory to first-line treatments. Many are initiated in secondary care.</li></ul>
                
        <details>
            <summary><strong>Gut-Brain Neuromodulators: <u>Strong Consensus</u></strong></summary>
            <div>
                <ul><li>- Both guidelines strongly endorse the use of neuromodulators, particularly TCAs.</li></ul>
                
        <details>
            <summary><strong>Tricyclic Antidepressants (TCAs)</strong></summary>
            <div>
                <ul><li>- <b>Strong recommendation FOR</b> TCAs (e.g., amitriptyline, desipramine) as a second-line drug for global symptoms and abdominal pain.</li><li>- <u>Mechanism</u>: Act on central pain pathways and have peripheral effects on motility.</li><li>- <u>BSG Dosing</u>: Start low (e.g., <q><b>10 mg</b> amitriptyline</q> at night) and titrate slowly up to a maximum of <q>30-50 mg</q> daily.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Selective Serotonin Reuptake Inhibitors (SSRIs)</strong></summary>
            <div>
                <ul><li>- <u>Weaker evidence than TCAs</u>.</li><li>- <u>BSG</u>: Weak recommendation for global symptoms.</li><li>- <u>ACG</u>: Notes their meta-analysis showed TCAs improved pain, but SSRIs did not.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatments for IBS-D</strong></summary>
            <div>
                
                
        <details>
            <summary><strong>Rifaximin: <u>Strong Consensus</u></strong></summary>
            <div>
                <ul><li>- A non-absorbable antibiotic.</li><li>- Both guidelines give a <b>strong recommendation FOR</b> rifaximin to treat global IBS-D symptoms.</li><li>- <u>BSG</u>: Notes its effect on abdominal pain is limited.</li><li>- <u>ACG</u>: Cites trials showing efficacy for both pain and stool consistency, and allows for up to two retreatments.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>5-HT3 Receptor Antagonists: <u>Strong Consensus</u></strong></summary>
            <div>
                <ul><li>- Includes alosetron and ondansetron.</li><li>- <u>BSG</u>: Weak recommendation. Notes alosetron is unavailable in many countries and suggests <b>ondansetron</b> as a reasonable alternative, titrated from <q>4 mg once daily</q> up to <q>8 mg TID</q>.</li><li>- <u>ACG</u>: Conditional recommendation for <b>alosetron</b> in women with severe symptoms who have failed conventional therapy, under the REMS program.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Eluxadoline: <u>Strong Consensus</u></strong></summary>
            <div>
                <ul><li>- A mixed opioid receptor agonist.</li><li>- Both guidelines recommend it for IBS-D.</li><li>- <u>Crucial Contraindications</u>: Prior cholecystectomy, history of pancreatitis, alcohol dependence, or severe liver impairment.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Bile Acid Sequestrants: <u>Discrepancy in Approach</u></strong></summary>
            <div>
                <ul><li>- <u>BSG</u>: Recommends testing for Bile Acid Diarrhoea (BAD) and treating if positive, implying use of sequestrants.</li><li>- <u>ACG</u>: Conditional recommendation <b>AGAINST</b> their use for global IBS-D symptoms, citing a lack of controlled trials. Suggests empiric therapy is a reasonable clinical option if BAD is suspected.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatments for IBS-C</strong></summary>
            <div>
                
                
        <details>
            <summary><strong>Secretagogues: <u>Strong Consensus</u></strong></summary>
            <div>
                <ul><li>- Both guidelines give <b>strong recommendations FOR</b> secretagogues.</li></ul>
                
        <details>
            <summary><strong>Guanylate Cyclase-C (GC-C) Agonists</strong></summary>
            <div>
                <ul><li>- <b>Linaclotide</b> and <b>Plecanatide</b>.</li><li>- <u>BSG</u>: Linaclotide is likely the most efficacious secretagogue available.</li><li>- <u>Common side effect</u>: Diarrhoea.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Chloride Channel Activators</strong></summary>
            <div>
                <ul><li>- <b>Lubiprostone</b>.</li><li>- <u>BSG</u>: Less likely to cause diarrhoea than other secretagogues.</li><li>- <u>Common side effect</u>: Nausea.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Sodium-Hydrogen Exchange Inhibitors</strong></summary>
            <div>
                <ul><li>- <b>Tenapanor</b>.</li><li>- <u>Common side effect</u>: Diarrhoea.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>5-HT4 Receptor Agonists: <u>Consensus</u></strong></summary>
            <div>
                <ul><li>- <b>Tegaserod</b>.</li><li>- Both guidelines note its efficacy but highlight its restricted availability (US only) and use (women <65 with ≤1 CV risk factor) due to cardiovascular safety concerns.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Psychological Therapies: <u>Strong Consensus</u></strong></summary>
            <div>
                <ul><li>- Both guidelines strongly recommend gut-directed psychotherapies for global IBS symptoms, especially for patients with refractory symptoms.</li></ul>
                
        <details>
            <summary><strong>Recommended Modalities</strong></summary>
            <div>
                <ul><li>- <b>Cognitive Behavioural Therapy (CBT)</b>: Strong evidence for efficacy, can be delivered face-to-face, by telephone, or web-based.</li><li>- <b>Gut-Directed Hypnotherapy (GDH)</b>: Strong evidence for efficacy, modulates the gut-brain axis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Timing of Referral</strong></summary>
            <div>
                <ul><li>- <u>BSG</u>: Consider when symptoms have not improved after <q>12 months</q> of drug treatment, but can be offered earlier based on patient preference and local availability.</li><li>- <u>ACG</u>: Presented as a general treatment option without a specific timeline.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management of Severe or Refractory IBS</strong></summary>
            <div>
                <ul><li>- <u>Consensus</u>: This population requires a careful, integrated, and multidisciplinary approach.</li></ul>
                
        <details>
            <summary><strong>Key Principles</strong></summary>
            <div>
                <ul><li>- <b>Review the diagnosis</b> and consider further targeted investigation.</li><li>- Manage with an <b>integrated multidisciplinary team</b> (gastroenterologist, dietitian, psychologist).</li><li>- <b><u>Primum non nocere</u> (First, do no harm)</b>: Avoid iatrogenic harms from opioid prescribing, unnecessary surgery (e.g., cholecystectomy, hysterectomy), and unproven therapies.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Advanced Pharmacotherapy (BSG)</strong></summary>
            <div>
                <ul><li>- <b>Augmentation</b>: Consider using combination gut-brain neuromodulators (e.g., TCA + SNRI).</li><li>- Requires vigilance for risks of <u>serotonin syndrome</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Fecal Microbiota Transplantation (FMT)</strong></summary>
            <div>
                <ul><li>- <u>Strong Consensus</u>: Both guidelines recommend <b>AGAINST</b> the use of FMT for IBS outside of a research setting.</li></ul>
                
        <details>
            <summary><strong>Rationale</strong></summary>
            <div>
                <ul><li>- Meta-analyses of RCTs have shown <b>no significant benefit</b> of FMT compared to placebo.</li><li>- Some trials even showed placebo capsules were superior to donor stool capsules.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
